한글목차

희귀의약품 서비스 시장 규모는 최근 급성장하고 있습니다. 2025년 434억 달러에서 2026년에는 507억 5,000만 달러에 이르고, CAGR 16.9%의 성장이 전망되고 있습니다. 지난 수년간의 성장 요인으로는 희귀질환의 지정 증가, 희귀질환 치료제 법제화 확대, 희귀질환 연구에 대한 투자 증가, 규제적 특혜, 환자 지원 단체의 역할 확대 등을 꼽을 수 있습니다.

향후 몇 년간 희귀의약품 서비스 시장 규모는 급성장이 전망됩니다. 2030년에는 939억 3,000만 달러에 이르고, CAGR은 16.6%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 개인 맞춤형 치료법에 대한 수요 증가, 첨단 임상시험 기술 도입 확대, 세계 희귀질환 치료제 파이프라인 확대, 실제 데이터 활용 확대, 희귀질환 치료제 개발에 대한 지속적인 규제 지원 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 전문 규제 및 개발 서비스에 대한 수요 증가, 신속 승인 프로세스 중시, 데이터 기반 희귀질환 연구 플랫폼 활용 확대, 환자 중심 임상 개발 모델 확대, 이해관계자간 협력 강화 등을 꼽을 수 있습니다.

희귀질환에 대한 투자 증가는 향후 몇 년간 희귀의약품 서비스 시장의 성장을 견인할 것으로 예측됩니다. 희귀질환은 인구의 극히 일부(일반적으로 2,000명 중 1명 미만)에게만 영향을 미치는 질환을 말합니다. 이러한 질환은 만성화 및 진행성 질환인 경우가 많으며, 생명을 위협하거나 신체적 장애를 유발할 수 있습니다. 희귀질환에 대한 투자는 주로 미충족 수요에 대한 인식 증가와 희귀질환 치료제 지정, 시장 독점권, 개발 비용 절감과 같은 규제적 특혜를 통한 큰 수익 가능성에 의해 주도되고 있습니다. 희귀질환에 대한 투자 확대는 연구개발에 대한 자금 지원을 확대하고, 그동안 간과되어 왔던 질환에 대한 치료제 개발을 가능하게 함으로써 희귀질환 치료제 서비스를 강화할 수 있습니다. 임상시험, 규제 당국의 승인, 환자 접근을 지원하여 약물의 보급을 가속화하고 희귀질환 환자들의 치료 옵션을 개선합니다. 예를 들어, 미국 비영리단체 Global Genes에 따르면 2024년 4월 기준 희귀질환 치료제를 개발하는 기업들은 2024년 1분기에 71억 달러의 자금을 조달했습니다. 이는 2023년 같은 기간의 18억 달러에 비해 307% 증가한 수치입니다. 그 결과, 희귀질환에 대한 투자 증가가 희귀의약품 서비스 시장의 성장을 가속하고 있습니다.

희귀질환 치료제 서비스 시장에서 사업을 전개하는 주요 기업들은 희귀질환 치료제 개발 및 보급을 가속화하기 위해 규제 당국의 승인 획득을 최우선 과제로 삼고 있습니다. 규제 당국의 승인은 정부 기관의 공식적인 승인으로, 의약품이나 치료법을 환자에게 합법적으로 시험, 제조, 판매할 수 있는 권한을 부여하는 것입니다. 예를 들어, 2023년 2월 미국 유전자치료제 기업 Askbio GmbH는 사지변형근이영양증(LGMD)에 대한 신규 임상시험 단계의 유전자치료제 'AB-1003'에 대해 유럽위원회로부터 희귀질환치료제 지정을 획득했습니다. 이 아데노부수체 바이러스(AAV) 기반 치료법은 단회 정맥 투여를 통해 근육 세포 내 FKRP 효소 활성을 회복시키는 것을 목표로 합니다. AB-1003은 유럽연합 집행위원회와 미국 식품의약국(FDA)으로부터 희귀질환 치료제 지정을 받았으며, FDA로부터 희귀 소아질환 지정 및 패스트트랙 지정을 받아 미충족 의료 수요의 시급성을 강조하고 있습니다. 현재 유전자 검사로 확진된 성인 환자를 대상으로 제2형 I/R9 사지 띠형 근이영양증(LGMD2I/R9)에 대한 안전성 및 유효성을 평가하기 위한 임상 I/II상(LION-CS101)이 진행 중입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Orphan drugs service is a specialized area of healthcare and pharmaceutical support that concentrates on supporting the research, development, approval, and accessibility of medications designed to treat rare diseases, which impact only a small and often underserved segment of the population. This service is vital in ensuring that these crucial medications can successfully navigate the complex regulatory and development procedures, ultimately providing access to patients who have few or no alternative treatment options.

The primary categories of orphan drug services include congenital disease, genetic disease, tumors and cancer, chronic conditions, and others. Congenital diseases are medical conditions present from birth, resulting from genetic abnormalities, developmental issues during pregnancy, or environmental factors affecting fetal development. These drugs are utilized across various therapeutic areas, such as oncology, metabolic disorders, neurological disorders, hematology, infectious diseases, and more, and are applicable for both adults and children.

Tariffs are impacting the orphan drugs service market by increasing costs of imported laboratory reagents, clinical trial equipment, data management systems, and specialized pharmaceutical inputs required for rare disease drug development. Service providers in North America and Europe are most affected due to reliance on globally sourced research tools, while Asia-Pacific faces higher costs for export-oriented development services. These tariffs are increasing service delivery costs and extending development timelines. However, they are also encouraging regional service localization, domestic research infrastructure investment, and stronger local regulatory support ecosystems.

The orphan drugs service market research report is one of a series of new reports from The Business Research Company that provides orphan drugs service market statistics, including orphan drugs service industry global market size, regional shares, competitors with a orphan drugs service market share, detailed orphan drugs service market segments, market trends and opportunities, and any further data you may need to thrive in the orphan drugs service industry. This orphan drugs service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The orphan drugs service market size has grown rapidly in recent years. It will grow from $43.4 billion in 2025 to $50.75 billion in 2026 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to growth in rare disease identification, expansion of orphan drug legislation, increasing investment in rare disease research, availability of regulatory incentives, rising role of patient advocacy groups.

The orphan drugs service market size is expected to see rapid growth in the next few years. It will grow to $93.93 billion in 2030 at a compound annual growth rate (CAGR) of 16.6%. The growth in the forecast period can be attributed to increasing demand for personalized rare disease therapies, rising adoption of advanced clinical trial technologies, expansion of global orphan drug pipelines, growing use of real-world evidence, continued regulatory support for orphan drug development. Major trends in the forecast period include increasing demand for specialized regulatory and development services, growing focus on accelerated approval pathways, rising use of data-driven rare disease research platforms, expansion of patient-centric clinical development models, enhanced collaboration between stakeholders.

The increasing investment in rare diseases is expected to drive the growth of the orphan drugs service market in the coming years. A rare disease is a medical condition that affects a small portion of the population, generally fewer than 1 in 2,000 individuals. These conditions are often chronic, progressive, and can be life-threatening or disabling. Investment in rare diseases is largely driven by the rising recognition of unmet medical needs and the potential for significant returns through regulatory incentives such as orphan drug designation, market exclusivity, and lower development costs. Rising investment in rare diseases strengthens orphan drug services by providing greater funding for research and development, enabling the creation of therapies for previously overlooked conditions. It speeds up drug availability by supporting clinical trials, regulatory approvals, and patient access, thereby improving treatment options for individuals with rare diseases. For example, in April 2024, according to Global Genes, a US-based nonprofit organization, companies working on drugs for rare diseases raised $7.1 billion in the first quarter of 2024, representing a 307% increase compared to the $1.8 billion raised in the same period in 2023. Consequently, the increasing investment in rare diseases is fueling the growth of the orphan drugs service market.

Major companies operating in the orphan drugs service market are prioritizing obtaining regulatory approvals to accelerate the development and accessibility of treatments for rare diseases. Regulatory approvals are official authorizations from government agencies that permit a drug or therapy to be legally tested, manufactured, and marketed for patient use. For example, in February 2023, Askbio GmbH, a US-based gene therapy company, was granted the European Commission orphan drug designation for AB-1003, a novel investigational gene therapy for limb-girdle muscular dystrophy. This adeno-associated virus (AAV)-based therapy is designed to restore FKRP enzyme activity in muscle cells through a single intravenous infusion. AB-1003 has received orphan drug designation from both the European Commission and the U.S. Food and Drug Administration (FDA), as well as rare pediatric disease and fast track designations from the FDA, emphasizing the urgent unmet medical need. It is currently being evaluated in a Phase 1/2 clinical trial (LION-CS101) to assess safety and efficacy in adults with genetically confirmed limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

In April 2025, Norgine B.V., a pharmaceutical company based in the Netherlands, acquired Theravia Pharma for an undisclosed sum. Through this acquisition, Norgine aims to strengthen its growth trajectory and rare disease portfolio by broadening its range of transformative therapies for patients with significant unmet medical needs in Europe and ANZ, positioning Norgine as a key partner in rare and specialty pharmaceuticals. Theravia Pharma is a pharmaceutical company based in France that specializes in rare diseases and orphan drug services.

Major companies operating in the orphan drugs service market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, AstraZeneca PLC, The Bristol-Myers Squibb Company, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., IQVIA Inc., CSL Behring GmbH, Lonza Group AG, BioMarin Pharmaceutical Inc., Fortrea Holdings Inc., Medpace Inc., Sarepta Therapeutics, Caidya Inc., Cevidra Inc.

North America was the largest region in the orphan drugs service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orphan drugs service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the orphan drugs service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The orphan drugs service market includes revenues earned by entities through clinical trial management, pharmacovigilance and safety monitoring, distribution and supply chain services, patient support and access programs, and data management and biostatistics services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Orphan Drugs Service Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses orphan drugs service market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for orphan drugs service ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The orphan drugs service market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Congenital Disease; Genetic Disease; Tumors And Cancer; Chronic; Other Types
• 2) By Therapeutic Area: Oncology; Metabolic Disorders; Neurological Disorders; Hematology; Infectious Diseases; Other Rare Diseases
• 3) By Application: Aldult; Children
• Subsegments:
• 1) By Congenital Disease: Heart Defects; Cleft Lip And Palate; Spina Bifida; Down Syndrome
• 2) By Genetic Disease: Cystic Fibrosis; Huntington Disease; Sickle Cell Anemia; Muscular Dystrophy
• 3) By Tumors And Cancer: Leukemia; Lymphoma; Neuroblastoma; Sarcoma
• 4) By Chronic: Rare Metabolic Disorders; Rare Endocrine Disorders; Rare Cardiovascular Disorders; Rare Neurological Disorders
• 5) By Other Types: Rare Infectious Diseases; Rare Immunological Disorders; Rare Dermatological Conditions; Rare Ophthalmological Disorders
• Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Pfizer Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.; Novartis AG; AstraZeneca PLC; The Bristol-Myers Squibb Company; GSK plc.; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Amgen Inc.; IQVIA Inc.; CSL Behring GmbH; Lonza Group AG; BioMarin Pharmaceutical Inc.; Fortrea Holdings Inc.; Medpace Inc.; Sarepta Therapeutics; Caidya Inc.; Cevidra Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Orphan Drugs Service Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Orphan Drugs Service Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Orphan Drugs Service Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Orphan Drugs Service Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Fintech, Blockchain, Regtech & Digital Finance
• 4.2. Major Trends
  • 4.2.1 Increasing Demand For Specialized Regulatory And Development Services
  • 4.2.2 Growing Focus On Accelerated Approval Pathways
  • 4.2.3 Rising Use Of Data-Driven Rare Disease Research Platforms
  • 4.2.4 Expansion Of Patient-Centric Clinical Development Models
  • 4.2.5 Enhanced Collaboration Between Stakeholders

5. Orphan Drugs Service Market Analysis Of End Use Industries

• 5.1 Pharmaceutical Companies
• 5.2 Biotechnology Firms
• 5.3 Hospitals And Clinics
• 5.4 Research Organizations
• 5.5 Rare Disease Treatment Centers

6. Orphan Drugs Service Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Orphan Drugs Service Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Orphan Drugs Service PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Orphan Drugs Service Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Orphan Drugs Service Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Orphan Drugs Service Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Orphan Drugs Service Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Orphan Drugs Service Market Segmentation

• 9.1. Global Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Congenital Disease, Genetic Disease, Tumors And Cancer, Chronic, Other Types
• 9.2. Global Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncology, Metabolic Disorders, Neurological Disorders, Hematology, Infectious Diseases, Other Rare Diseases
• 9.3. Global Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Aldult, Children
• 9.4. Global Orphan Drugs Service Market, Sub-Segmentation Of Congenital Disease, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Heart Defects, Cleft Lip And Palate, Spina Bifida, Down Syndrome
• 9.5. Global Orphan Drugs Service Market, Sub-Segmentation Of Genetic Disease, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cystic Fibrosis, Huntington Disease, Sickle Cell Anemia, Muscular Dystrophy
• 9.6. Global Orphan Drugs Service Market, Sub-Segmentation Of Tumors And Cancer, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Leukemia, Lymphoma, Neuroblastoma, Sarcoma
• 9.7. Global Orphan Drugs Service Market, Sub-Segmentation Of Chronic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Rare Metabolic Disorders, Rare Endocrine Disorders, Rare Cardiovascular Disorders, Rare Neurological Disorders
• 9.8. Global Orphan Drugs Service Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Rare Infectious Diseases, Rare Immunological Disorders, Rare Dermatological Conditions, Rare Ophthalmological Disorders

10. Orphan Drugs Service Market Regional And Country Analysis

• 10.1. Global Orphan Drugs Service Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Orphan Drugs Service Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Orphan Drugs Service Market

• 11.1. Asia-Pacific Orphan Drugs Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Orphan Drugs Service Market

• 12.1. China Orphan Drugs Service Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Orphan Drugs Service Market

• 13.1. India Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Orphan Drugs Service Market

• 14.1. Japan Orphan Drugs Service Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Orphan Drugs Service Market

• 15.1. Australia Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Orphan Drugs Service Market

• 16.1. Indonesia Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Orphan Drugs Service Market

• 17.1. South Korea Orphan Drugs Service Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Orphan Drugs Service Market

• 18.1. Taiwan Orphan Drugs Service Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Orphan Drugs Service Market

• 19.1. South East Asia Orphan Drugs Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Orphan Drugs Service Market

• 20.1. Western Europe Orphan Drugs Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Orphan Drugs Service Market

• 21.1. UK Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Orphan Drugs Service Market

• 22.1. Germany Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Orphan Drugs Service Market

• 23.1. France Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Orphan Drugs Service Market

• 24.1. Italy Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Orphan Drugs Service Market

• 25.1. Spain Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Orphan Drugs Service Market

• 26.1. Eastern Europe Orphan Drugs Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Orphan Drugs Service Market

• 27.1. Russia Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Orphan Drugs Service Market

• 28.1. North America Orphan Drugs Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Orphan Drugs Service Market

• 29.1. USA Orphan Drugs Service Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Orphan Drugs Service Market

• 30.1. Canada Orphan Drugs Service Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Orphan Drugs Service Market

• 31.1. South America Orphan Drugs Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Orphan Drugs Service Market

• 32.1. Brazil Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Orphan Drugs Service Market

• 33.1. Middle East Orphan Drugs Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Orphan Drugs Service Market

• 34.1. Africa Orphan Drugs Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Orphan Drugs Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Orphan Drugs Service Market Regulatory and Investment Landscape

36. Orphan Drugs Service Market Competitive Landscape And Company Profiles

• 36.1. Orphan Drugs Service Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Orphan Drugs Service Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Orphan Drugs Service Market Company Profiles
  • 36.3.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

37. Orphan Drugs Service Market Other Major And Innovative Companies

• Sanofi S.A., Novartis AG, AstraZeneca PLC, The Bristol-Myers Squibb Company, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., IQVIA Inc., CSL Behring GmbH, Lonza Group AG, BioMarin Pharmaceutical Inc., Fortrea Holdings Inc., Medpace Inc., Sarepta Therapeutics

38. Global Orphan Drugs Service Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Orphan Drugs Service Market

40. Orphan Drugs Service Market High Potential Countries, Segments and Strategies

• 40.1 Orphan Drugs Service Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Orphan Drugs Service Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Orphan Drugs Service Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer